| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 上海复旦张江生物医药股份有限公司，一九九六年十一月创建于上海浦东张江高科技园区，由知名企业如上海医药集团股份有限公司等作为公司股东。 本着“我们多一分探索、人类多一分健康”的信念，公司主要从事生物医药的创新研究、开发、生产和销售，力求成为一家以知识产权为核心源泉的生物医药创新企业。经过多年的不懈努力，公司在基因技术药物、光动力技术药物、纳米技术药物及口服固体制剂技术药物等领域不断推出新技术及产品，形成了明显的竞争优势，预计未来将陆续有新药投放市场。 凭籍在生物医药领域的实力，公司多次承担“国家重点科技项目（攻关）计划”、“国家高技术研究发展计划（八六三计划）”、“‘重大新药创制’科技重大专项”等。一九九八年以来，复旦张江被连续认定为上海市“高新技术企业”；一九九九年，公司被国家人事部批准为“企业博士后科研工作站”。于二零零二年八月，公司在香港创业版成功上市（股票代码：8231），并于二零一三年十二月，转往香港主板上市（股票代码：1349）。二零二零年六月，公司在上海证券交易所科创板上市交易（股票代码：688505）。至此，复旦张江成为于A+H两地上市的公司之一。 公司现控股泰州复旦张江药业有限公司，上海溯源生物技术有限公司及风屹（香港）控股有限公司。公司人力资源丰富，技术力量强大，近六百名高素质的员工推动公司不断创新，实现飞跃。 | ||||||||||||||||||||||||
| Main Business | 主要从事生物医药的创新研究开发、生产制造和市场营销。 | ||||||||||||||||||||||||
| Legal Representative | 赵大君 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 薛燕 | ||||||||||||||||||||||||
| Solicitors | 上海市方达律师事务所 | ||||||||||||||||||||||||
| Auditors | 普华永道中天会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-58553583 | ||||||||||||||||||||||||
| Fax No | 021-58553583 | ||||||||||||||||||||||||
| Website | www.fd-zj.com | ||||||||||||||||||||||||
| fd-zj@fd-zj.com；ir@fd-zj.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 19/06/2020 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.110 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.070 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.270 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.422B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |